[
    {
        "id": "osp-12596",
        "type": "article-journal",
        "title": "Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population",
        "author": [
            {
                "family": "Al-Hinai",
                "given": "Ahmed"
            },
            {
                "family": "Wali",
                "given": "Upender Krishen"
            },
            {
                "family": "Rasool",
                "given": "Tayseer Abdul"
            },
            {
                "family": "Rizvi",
                "given": "Syed G."
            }
        ],
        "URL": "https://omanscience.com/en/articles/experience-of-intravitreal-triamcinolone-acetonide-for-treatment-of-diabetic-macular-edema-among-omani-population",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2017
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "10",
        "issue": "3",
        "page": "177-183",
        "DOI": "10.4103/ojo.ojo_173_2016",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Purpose: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME).\n\nMaterials and methods: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thickness. All eyes were injected with a single IVT injection of preservative free triamcinolone acetonide (TA) with dose of 4 mg. Patients were subjected to visual acuity (VA) and OCT on each follow-up visit which was continued for 6 months. The total number of IVT injections given was 48. Six eyes had a repeat injection. None of the eyes had any other IVT injection within 6 weeks of TA. Twenty-one eyes were pseudophakic.\n\nResults: Mean age of the patients was 58.8 years. The mean central subfield thickness (CST) at baseline was 504.6 μm. At 6 weeks, the mean CST dropped by 183.6 μm (P < 0.00001). At 6-month follow-up, the mean CST had increased by 74.6 μm from 6 weeks level; however, the 6-month mean CST was 109 μ less than mean baseline thickness (P < 0.0005). The mean baseline VA was 0.80 LogMAR units. At 6 weeks, the mean VA dropped by 0.01 LogMAR. At 6 months, VA improved by 0.02 LogMAR units from baseline. Overall, VA improved in 47% eyes, dropped from baseline in 35% eyes, and remained unchanged in 18% eyes.\n\nConclusion: Triamcinolone acetonide is a safe, effective, and promising therapy in DME."
    }
]